Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
151 hedge funds and large institutions have $1.39B invested in Esperion Therapeutics in 2015 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 70 increasing their positions, 26 reducing their positions, and 35 closing their positions.
169% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 26
125% more call options, than puts
Call options by funds: $139M | Put options by funds: $61.6M
29% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 35
7% more funds holding
Funds holding: 141 → 151 (+10)
1% more capital invested
Capital invested by funds: $1.38B → $1.39B (+$8.72M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$123M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$30.5M |
| 3 |
CCI
Columbus Circle Investors
|
+$28.8M |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$21.7M |
| 5 |
SAM
Senzar Asset Management
New York
|
+$15.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$60M |
| 2 |
AC
Aisling Capital
New York
|
-$40.9M |
| 3 |
ICAP
Independence Capital Asset Partners
Denver,
Colorado
|
-$14.7M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$10.2M |
| 5 |
JP Morgan Chase
New York
|
-$9.97M |
ESPR Hedge Fund Activity: Q2 2015 in Review
151 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q2 2015, worth a combined $1.39B — up 0.63% from $1.38B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new ESPR positions and 35 closed out — a net gain of 10 holders — while 70 added to existing stakes and 26 trimmed.
The largest buyer was Viking Global Investors, adding an estimated $123M. The largest seller was Visium Asset Management, cutting an estimated $60M.
- 151 institutional investors held Esperion Therapeutics (ESPR) as of Q2 2015, up from 141 in Q1 2015.
- Funds reported $1.39B of Esperion Therapeutics stock for Q2 2015, up 0.63% quarter-over-quarter.
- 45 funds opened new Esperion Therapeutics positions in Q2 2015 and 35 closed out, a net change of +10 holders.
- The largest Esperion Therapeutics buyer in Q2 2015 was Viking Global Investors, an estimated $123M added.
- The largest Esperion Therapeutics seller in Q2 2015 was Visium Asset Management, an estimated $60M sold.
Based on aggregated 13F filings for Q2 2015.